• FDA committee fails to recommend Linhaliq for chronic lung infection

    9 monthes ago - By Healio

    Aradigm Corporation recently announced that the FDA's Antimicrobial Drugs Advisory Committee did not recommend approval for Linhaliq to treat patients with noncystic fibrosis bronchiectasis who have chronic lung infections caused by Pseudomonas aeruginosa.
    According to a press release, the FDA committee was asked if Aradigm “provided substantial evidence of the safety and efficacy of ciprofloxacin dispersion for inhalation in delaying the time to first exacerbation after starting treatment in noncystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas
    Read more ...